Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-19
2011-12-13
Wang, ShengJun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211090, C514S275000
Reexamination Certificate
active
08076321
ABSTRACT:
The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).
REFERENCES:
patent: 6545634 (2003-04-01), Heide et al.
patent: 2003/0170720 (2003-09-01), van der Kuyl et al.
patent: 2005/027971 (2005-03-01), None
patent: 2005/049032 (2005-06-01), None
patent: 2006/135790 (2006-12-01), None
Pettigrew et al. (Contemporary challenges in mastocytosis, Clin Rev Allergy Immunol. Apr. 2010; 38(2-3): 125-34.
Kluin-Nelemans Hanneke C et al. “Cladribine Therapy for Systemic Mastocytosis”, Blood, vol. 102, No. 13, pp. 4270-4276, (2003).
Shah Neil P et al. “BMS-354825 is a SRC/ABL Inhibitor With High Nanomolar Activity Against The Kit D816V Mutation, Which Drives Systemic Mastocytosis and is Imatinib-Resistant”, Blood, vol. 104, No. 11, part 1, pp. 228A, (2004).
Gleixner K V et al. “PKC412 Inhibits In Vitro Growth of Neoplastic Human Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107, Imatinib, and Cladribine (2CdA) and Evaluation of Cooperative Drug Effects”, Blood vol. 107, No. 2, pp. 752-759 (2005).
Pardanani et al. “Pathogenesis, Clinical Features and Treatment Advanced in Mastocytosis”, Best Practice & Research Clinical Haematology, vol. 19, No. 3, pp. 595-615 (2006).
Barbie D A et al. “Systemic Mastocytosis: Current Classification and Novel Therapeutic Options”, Clinical Advanced in Hematology and Oncology 2006 United States, vol. 4, No. 10, pp. 768-775.
Perez-Perez Maria-Jesus et al. “Mitochondrial Thymidine Kinase Inhibitors”, Current Topics in Medicinal Chemistry, Bentham Science Publishers, vol. 5, No. 13, pp. 1205-1219 (2005).
Chalandon Y et al. “Targeting Mutated Protein Tyrosine Kinases and Their Signaling Pathways in Hematologic Malignancies”, Haematologica 2005 Italy, vol. 90, No. 7, pp. 949-968 (2005).
English Translation of Russian Office Action dated Jul. 21, 2010.
Betton Timothy E
Dohmann George R.
Wang ShengJun
LandOfFree
Compositions for treatment of systemic mastocytosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treatment of systemic mastocytosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment of systemic mastocytosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312390